Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate CancerChristopher J. Sweeney, Robert S. DiPaola, Robert Dreicer et al.|New England Journal of Medicine|2015Cited by 2.8k
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED TrialChristos E. Kyriakopoulos, Christopher J. Sweeney, Yu‐Hui Chen et al.|Journal of Clinical Oncology|2018Cited by 1.1k
Therapy-Induced Senescence in CancerJonathan A. Ewald, David F. Jarrard|JNCI Journal of the National Cancer Institute|2010Cited by 822
Overexpression of the Novel Senescence Marker β-Galactosidase (GLB1) in Prostate Cancer Predicts Reduced PSA RecurrenceJennifer Wagner, David F. Jarrard|PLoS ONE|2015Cited by 80
Persistence of senescent prostate cancer cells following prolonged neoadjuvant androgen deprivation therapyMichael L. Blute, David F. Jarrard|PLoS ONE|2017Cited by 34